Authors
Ronit Juthani, Caiwei Zhong, Ali Tarhini, Miguel Muniz, Wanling Xie, Hailey Stoltenberg, Andrew Wolanski, Jolivette Ritzer, Xiao X Wei, Heather Jacene, Daniel S Childs, Praful Ravi
Published in
Prostate cancer and prostatic diseases. Nov 14, 2026. Epub Nov 14, 2026.
Abstract
The prognostic impact of neutrophil-lymphocyte ratio (NLR) in patients receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration-resistant prostate cancer (mCRPC) is unclear.
This was a retrospective analysis of 501 patients receiving LuPSMA for mCRPC post-taxane across two institutions between 2022 and 2024.
NLR > 3 at cycle 1 was an independent predictor of poorer survival, and patients with NLR > 3 at cycle 1 and cycle 2 had the poorest outcomes.
NLR > 3 is an adverse prognostic factor in patients receiving LuPSMA, and early NLR dynamics may be helpful in identifying patients who require closer disease monitoring during therapy.
PMID:
43034183
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0